Glucosamine and chondroitin in the management of osteo-arthritis

Glucosamine and/or chondroitin for the management of osteo-arthritis \textbf{WILL NOT} be routinely funded.

<table>
<thead>
<tr>
<th>Strength of evidence</th>
<th>Clinical Effectiveness</th>
<th>Cost Effectiveness</th>
</tr>
</thead>
<tbody>
<tr>
<td>Strength of evidence</td>
<td>Inadequate</td>
<td>Inadequate</td>
</tr>
</tbody>
</table>

\textbf{Comments}

The National Institute for Health and Care Excellence carried out an extensive systematic review and critical appraisal of the evidence of effectiveness of glucosamine and chondroitin for the management of osteo-arthritis. The quality of the evidence reviewed ranged from very low to moderate. Overall, NICE concluded that the evidence of effectiveness was limited, uncertain and inadequate to support a positive recommendation. The inadequate evidence of effectiveness meant that cost effectiveness could not be considered.

[NICE, Osteo-arthritis full guideline, 2014, section 8.4

\textbf{Summary of evidence}

National Institute for Health and Care Excellence, Osteo-arthritis care and management, Clinical Guideline 117, 2014, section 8.4

\textbf{Reason for Requesting policy:}

Reviewed as part of the Effective Use of Resources Project.
Where a patient is considered to have exceptional need for and capacity to benefit from a treatment that is not routinely funded, a request for individual funding may be made to the Individual Funding Requests Panel. The patient must be made aware that the Panel may not support the request and must not be given any expectation that they will be able to have the treatment until a decision to fund has been received in writing from the Panel.

For further information contact:

Tel: +44 (0)1624 642646
Email: clinicalcommissioning.dhsc@gov.im
Website: www.gov.im/dhscclinicalcommissioning